Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer

NCT05501769 is registered in ClinicalTrials.gov with Arvinas Estrogen Receptor, Inc. as lead sponsor.

NCT NCT05501769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05501769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer
Lead sponsor
Arvinas Estrogen Receptor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 8, 2022
Completion date
August 25, 2025
Enrollment
32 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer